Weekly aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings on May 17, 2018

May 17, 2018 - By Pearl Odom

aTyr Pharma, Inc. (NASDAQ:LIFE) Corporate Logo

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

In total 3 analysts cover aTyr Pharma (NASDAQ:LIFE). “Buy” rating has 0, “Sell” are 3, while 0 are “Hold”. (NASDAQ:LIFE) has 0 bullish analysts. 3 are the (NASDAQ:LIFE)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Wednesday, February 14 the company was downgraded by JP Morgan. On Tuesday, May 15 the company was downgraded by Citigroup. In Wednesday, February 14 report J.P. Morgan downgraded the stock to “Sell” rating. Listed here are aTyr Pharma, Inc. (NASDAQ:LIFE) PTs and latest ratings.

15/05/2018 Broker: Citigroup Rating: Sell New Target: $1.0000 Downgrade
14/02/2018 Broker: J.P. Morgan Rating: Sell Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade

LIFE is reaching $0.95 during the last trading session, after increased 11.20%.aTyr Pharma, Inc. is downtrending after having declined 19.01% since May 17, 2017. LIFE has 1.04 million volume or 681.58% up from normal. LIFE underperformed the S&P 500 by 30.56%.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases.The company has $28.17 million market cap. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy.Currently it has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

For more aTyr Pharma, Inc. (NASDAQ:LIFE) news posted recently go to: Nasdaq.com, Benzinga.com, Benzinga.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 …” posted on May 17, 2018, “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” on May 16, 2018, “Benzinga Pro’s 5 Stocks To Watch Today” with a publish date: May 17, 2018, “Mid-Afternoon Market Update: Precipio Surges Following Strong Preliminary Q1 Results; aTyr Pharma Shares Slide” and the last “Premarket analyst action – healthcare” with publication date: May 15, 2018.

aTyr Pharma, Inc. (NASDAQ:LIFE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.